DUAKLIR® GENUAIR® approved in the EUROPEAN union FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Approximately 300 million people1 around the world live with COPD, a progressive and chronic disease where people find breathing difficult due to limited airflow. Improving the lung function and managing daily symptoms such as breathlessness are important to the management of COPD. Duaklir is a fixed-dose combination of already-approved Eklira® (aclidinium bromide), a long-acting muscarinic-antagonist (LAMA), with the long-acting beta -agonist (LABA) formoterol. The twice-daily therapy is the only LAMA/LABA combination to show statistically significant improvement in breathlessness compared to individual therapies and is administered by the Genuair® dry powder inhaler device. AstraZeneca owns the rights to develop and commercialise Duaklir Genuair in the European Union (EU) following the strategic business combination of Almirall's respiratory portfolio, which was completed (http://www.astrazeneca.com/Media/Press-releases/Article/20140311- -astrazeneca-completes-strategic-transaction) last month. The EU approval of Duaklir Genuair marks an important further step in AstraZeneca's inhaled therapy strategy of providing physicians and patients a choice of products uniquely available in both dry powder and pressurised metered dose devices. "We are pleased to receive European regulatory approval for Duaklir Genuair as an innovative treatment for patients with COPD. Patients need treatments that can help to improve their lung function and allow them to better manage the daily and debilitating symptoms of their condition, in turn improving their overall quality of life." said Briggs Morrison, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca. The EU approval of Duaklir Genuair was based on efficacy and safety data from more than 2,000 patients in 11 clinical studies, conducted in 29 countries worldwide. Results showed that Duaklir Genuair demonstrated statistically significant and sustained improvement in the lung function compared to monotherapy, providing a favourable benefit-to-risk profile. The EC marketing authorisation applies to all member states of the EU and the European Economic Area. Aclidinium bromide/formoterol fumarate will be marketed in Europe by AstraZeneca under the trade name Duaklir® Genuair®. About Duaklir® Genuair® Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12 mcg) is a fixed dose combination of two approved long-acting bronchodilators with different mechanisms of action and similar pharmocodynamic profiles. Aclidinium bromide is an anticholinergic or long acting muscarinic antagonist (LAMA) that produces bronchodilation by inhibiting the muscarinic M3 receptor in the airway smooth muscle. Formoterol fumarate is a long-acting beta-agonist (LABA) that stimulates the β2-receptors in the bronchial smooth muscle resulting in bronchodilation. Both aclidinium bromide (Eklira®) and formoterol fumarate are separately approved for the maintenance treatment of COPD in the United States and Europe. AstraZeneca owns the rights for the development and commercialisation of Almirall's proprietary respiratory business as well as its pipeline of investigational novel therapies. About Genuair® Genuair is a multi-dose, pre-loaded dry powder inhaler with a unique combination of optical and acoustic signals to reassure patients that the dose has been taken correctly. The inhaler's safety features ensure high levels of reliability while its easy-to-use features and design minimise the potential for misuse and are expected to increase patient acceptance and compliance. About Phase III Studies AUGMENT and ACLIFORM The Phase III clinical development programme included approximately 4,000 patients with a clinical diagnosis of COPD. The programme comprised of two 6 -month randomised, control- and active-controlled studies, ACLIFORM-COPD (LAC 30) - (ACLIdinium/FORMoterol fumarate combination for Investigative use in the treatment of moderate to severe COPD) and AUGMENT (LAC 31) - (Aclidinium/formoterol FUmurate Combination for InvestiGative use in the TreatMENT of Moderate to Severe COPD); a 6-month extension of the AUGMENT study (LAC 36); and a further long-term 12-month randomised controlled study comparing aclidinium/formoterol 340/12 to formoterol (LAC 32). About COPD Chronic obstructive pulmonary disease (COPD) is a progressive and chronic disease which encompasses a number of lung conditions, including chronic bronchitis, emphysema and chronic obstructive airways disease. People with COPD have difficulty breathing due to persistent airflow limitation. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com 1 Decision Resources 2013 for G7 prevalence: http://www.decisionresources.com/Products-and...dbasim0213. Buist SA, McBurnie MA, et al. International variation in the prevalence of COPD (The BOLD Study), a population-based prevalence study; The Lancet (2007): http://www.thelancet.com/journals/lancet/arti...6(07)61377 -4/abstract, CONTACTS Media Enquiries Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Vanessa Rhodes +44 20 7604 8037 (UK/Global) Ayesha Bharmal +44 20 7604 8034 (UK/Global) Jacob Lund +46 8 553 260 20 (Sweden) Investor Enquiries Thomas Kudsk Larsen +44 20 7604 8199 mob: +44 7818 524185 Karl Hård +44 20 7604 8123 mob: +44 7789 654364 Anthony Brown +44 20 7604 8067 mob: +44 7585 404943 Eugenia Litz +44 20 7604 8233 mob: +44 7884 735627 Christer Gruvris +44 20 7604 8126 mob: +44 7827 836825 24 November 2014 -ENDS-
DUAKLIR GENUAIR APPROVED IN THE EU FOR COPD DUAKLIR GENUAIR
Top 10 Most Recent News Articles
Oracle Takes AI to Construction's Messy Project Middle
A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...
Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour
A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...
Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal
Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...
Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand
A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...
Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again
A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...
Continue Reading
COPD Support Program Targets a Costly Care Gap Today
Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...
Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market
Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...
Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home
Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...
Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem
Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...
Continue Reading
ArchiPro Enters U.S. Design Market With Curated Bet
Blue-chip furniture and glossy project photos are not a moat by themselves, no matter how hard a platform tries to make them look like one. But ArchiPro’s full U.S. launch deserves a closer look because it arrives with something many would-be marketplace operators lack: more than a decade of operating history in New Zealand and Australia. A Three-Sided Machine Meets...
Continue ReadingTop 5 Most Recently Viewed Articles
Exploring the Growth of SOC-as-a-Service to $14.66 Billion
Understanding SOC-as-a-Service Market Growth The global SOC-as-a-Service market is projected to witness substantial growth, anticipated to reach a value of USD 14.66 billion by 2030. This growth surge represents a remarkable increase from USD 7.37 billion and reflects a compound annual growth rate (CAGR) of 12.2% during the period from 2024 to 2030. The surge in demand...
Continue Reading
Revolutionary Anti-Aging Hair Solution Launches for Men
Just For Men® Launches Gray Reverse™ Hair Serum In an exciting development for men's grooming, Just For Men® has unveiled its latest innovation, the Gray Reverse™ Hair Serum. This groundbreaking product is designed to help men fight against the signs of aging, specifically graying hair, and play a key role in maintaining their natural appearance. Understanding the...
Continue Reading
Legal Guidance for Lantheus Holdings Investors Amid Class Action
Introduction to Lantheus Holdings Lantheus Holdings, Inc. (NASDAQ: LNTH) stands as a significant player in the medical technology sector, specializing in diagnostic imaging and therapeutic agents. The company focuses on enhancing diagnosis, treatment, and monitoring of various health conditions. As it gears up for a challenging period marked by considerable scrutiny,...
Continue Reading
OpenAI Explores Development of Innovative Web Browser
OpenAI Explores Development of Innovative Web Browser OpenAI, the company behind the popular AI chatbot ChatGPT, is taking strategic steps that could reshape the landscape of web browsing. Recently, it has been reported that OpenAI is contemplating the creation of a new web browser that could work harmoniously with its advanced chatbot technologies. This potential...
Continue Reading
Mercedes-Benz Faces Challenges with New FY24 Financial Guidance
Mercedes-Benz Updates Fiscal Year 2024 Projections Recently, the Mercedes-Benz Group adjusted its financial outlook for the fiscal year 2024. Despite this reevaluation, Morgan Stanley has chosen to keep its Overweight rating on Mercedes-Benz (OTC: MBGAF) along with a solid price target of EUR 82.00. This decision comes even as the company revised its financial...
Continue Reading